Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
Loprinzi, Charles L. , Lacchetti, Christina , Bleeker, Jonathan , Chauhan, Cynthia, Hertz, Daniel L. , Kelley, Mark R. , Lavino, Antoinette, Lustberg, Maryam B. , Schneider, Bryan P. , Smith, Mary Lou , Wagner‐Johnston, Nina D. , Hertz, Daniel L , Lustberg, Maryam , Cavaletti, Guido , Paice, Judith A. , Lavoie Smith, Ellen M , Smith, Thomas J. , Hershman, Dawn L.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2020 | Volume: 38 | Issue: 28 | Pages: 3325-3348

10.1200/jco.20.01399 | PMID 32663120 Get It

PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited. Additional information is available at www.asco.org/survivorship-guidelines .
Triptolide-induced apoptosis in non-small cell lung cancer via a novel miR204-5p/Caveolin-1/Akt-mediated pathway
Philips, Brian J. , Bürki, Sarah, Ryan, John P. , Noda, Kentaro , D’Cunha, Jonathan, D'Cunha, Jonathan, Kumar, Ajay

Mayo Clinic

Oncotarget | July 14, 2020 | Volume: 11 | Issue: 28 | Pages: 2793-2806

10.18632/oncotarget.27672 | PMID 32733649 Get It

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors
Hálfdánarson, Þorvarður R. , Tang, Laura , Bellizzi, Andrew M. , Bergsland, Emily K. , Halperin, Daniel M. , Eads, Jennifer R. , Singh, Simron , Metz, David C. , Naraev, Boris G., Reidy‐Lagunes, Diane , Howe, James R. , Pommier, Rodney F. , Menda, Yusuf , Chan, Jennifer A. , Halfdanarson, Thorvardur R , Bellizzi, Andrew M , Howe, James R , Menda, Yusuf , Strosberg, Jonathan , O’Dorisio, Thomas M. , Fishbein, Lauren , Hope, Thomas A. , Salem, Riad

Mayo Clinic

Pancreas | July 14, 2020 | Volume: 49 | Issue: 7 | Pages: 863-881

10.1097/mpa.0000000000001597 | PMID 32675783 Get It

AbstractThis article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection. The available literature was reviewed for each of the question and panel members voted on controversial topics, and the recommendations were included in a document circulated to all panel members for a final approval.
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Persky, Daniel O. , Li, Hongli , Stephens, Deborah M. , Park, Steven I., Bartlett, Nancy L. , Swinnen, Lode J., Winegarden, Jerome D., FitzGerald, Thomas J. , Leonard, John P. , Song, Joo Y. , Fisher, Richard I., Smith, Sonali M. , Miller, Thomas P. , Friedberg, Jonathan W. , Park, Steven , Song, Joo Y , Bartlett, Nancy L , FitzGerald, Thomas J , Park, Steven I , Stephens, Deborah M , Barr, Paul M. , Constine, Louis S , Kahl, Brad S. , LeBlanc, Michael , Rimsza, Lisa M.

Mayo Clinic

Journal of Clinical Oncology | July 13, 2020 | Volume: 38 | Issue: 26 | Pages: 3003-3011

10.1200/jco.20.00999 | PMID 32658627 Get It

PURPOSEDiffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)–directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.METHODSPatients with nonbulky (< 10 cm) stage I/II untreated DLBCL received 3 cycles of standard R-CHOP therapy and underwent a centrally reviewed interim PET/computed tomography scan (iPET). Those with a negative iPET proceeded with 1 additional cycle of R-CHOP, whereas those with a positive iPET received involved field radiation therapy followed by ibritumomab tiuxetan radioimmunotherapy.RESULTSOf 158 patients enrolled, 132 were eligible and 128 underwent iPET, which was positive in 14 (11%) of the patients. With a median follow-up of 4.92 years (range, 1.1-7.7 years), only 6 patients progressed and 3 died as a result of lymphoma. Eleven patients died as a result of nonlymphoma causes at a median age of 80 years. The 5-year progression-free survival estimate was 87% (95% CI, 79% to 92%) and the OS estimate was 89% (95% CI, 82% to 94%), with iPET-positive and iPET-negative patients having similar outcomes.CONCLUSIONTo our knowledge, S1001 is the largest prospective study in the United States of limited-stage DLBCL in the rituximab era, with the best NCTN results in this disease subset. With PET-directed therapy, 89% of the patients with a negative iPET received R-CHOP × 4, and only 11% had a positive iPET and required radiation, with both groups having excellent outcomes. The trial establishes R-CHOP × 4 alone as the new standard approach to limited-stage disease for the absolute majority of patients.
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham, Neena S. , Inselman, Jonathan , Sangaralingham, Lindsey R. , Shah, Nilay D. , Yao, Xiaoxi , Yang, Eric H. , Noseworthy, Peter A. , Herrin, Jeph , Ngufor, Che

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 13, 2020 | Volume: 52 | Issue: 4 | Pages: 646-654

10.1111/apt.15790 | PMID 32657466 Get It

SummaryBackgroundGastrointestinal bleeding (GIB) frequently occurs following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) with the prescription of P2Y12 inhibiting antiplatelet agents. Compared with clopidogrel, the newer P2Y12 inhibitors lower major adverse cardiac events with similar or possibly higher major bleeding events. The comparative GIB rates of these medications remain poorly understood.AimTo compare GIB rates associated with clopidogrel, prasugrel and ticagrelor using national medical and pharmacy claims data from privately insured and Medicare Advantage enrollees .MethodsPropensity score and inverse probability treatment weighting were used to balance baseline characteristics among treatment groups. The 1‐year GIB risk was calculated using weighted Cox proportional hazard models and expressed as hazard ratios (HR) with 95% confidence intervals (CI) and number needed to harm (NNH).ResultsWe identified 37 019 patients with ACS (non‐ST elevation ACS [NSTE‐ACS] and ST‐elevation myocardial infarction [STEMI]) within 14 days of a PCI (mean age 63 years and 70% male). Clopidogrel prescription was most common (69%) with prasugrel (16%) and ticagrelor (14%) prescribed less frequently. When compared with clopidogrel, ticagrelor was associated with a 34% risk reduction (HR 0.66; 95% CI: 0.54–0.81) in GIB overall and with NSTE‐ACS, and a 37% GIB risk reduction (HR 0.63; 95% CI: 0.42–0.93) in STEMI patients. When compared with clopidogrel, prasugrel was associated with a 21% risk reduction (HR 0.79; 95% CI: 0.64–0.97) overall, a 36% GIB risk reduction (HR 0.64; 95% CI: 0.49–0.85) in STEMI patients but no reduction of GIB risk in NSTE‐ACS patients.ConclusionsIn the first year following PCI, ticagrelor or prasugrel are associated with fewer GIB events than clopidogrel.
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort
Gentry, Melanie T. , Syrjanen, Jeremy A. , Calvert, Kendrick J., Hughes, Samantha R., Brushaber, Danielle , Kremers, Walter K. , Bove, Jessica, Brannelly, Patrick , Coppola, Giovanni , Dheel, Christina, Dickinson, Susan, Faber, Kelley, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Deb, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Haley, Dana , Heuer, Hilary W. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kornak, John , Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Manoochehri, Masood , McGinnis, Scott, Miller, Bruce L. , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Sengdy, Pheth, Shaw, Leslie M. , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , Calvert, Kendrick, Hughes, Samantha, Irwin, David J , Hsiung, Gink-Yuek , Miller, Bruce L , Kantarci, Kejal , Gentry, Melanie T , Kremers, Walter K , Lapid, Maria I. , Dickerson, Bradley, Fong, Jamie , Foroud, Tatiana , Gearhart, Deb, Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Knopman, David S. , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | July 13, 2020 | Volume: 16 | Issue: 8 | Pages: 1115-1124

10.1002/alz.12095 | PMID 32656921 Get It

AbstractObjectiveThe Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects evaluates familial frontotemporal lobar degeneration (FTLD) kindreds with MAPT, GRN, or C9orf72 mutations. Objectives were to examine whether health‐related quality of life (HRQoL) correlates with clinical symptoms and caregiver burden, and whether self‐rated and informant‐rated HRQoL would correlate with each other.MethodsIndividuals were classified using the Clinical Dementia Rating (CDR®) Scale plus National Alzheimer's Coordinating Center (NACC) FTLD. HRQoL was measured with DEMQOL and DEMQOL‐proxy; caregiver burden with the Zarit Burden Interview (ZBI). For analysis, Pearson correlations and weighted kappa statistics were calculated.ResultsThe cohort of 312 individuals included symptomatic and asymptomatic individuals. CDR® plus NACC FTLD was negatively correlated with DEMQOL (r = −0.20, P = .001), as were ZBI and DEMQOL (r = −0.22, P = .0009). There was fair agreement between subject and informant DEMQOL (κ = 0.36, P <.0001).ConclusionLower HRQoL was associated with higher cognitive/behavior impairment and higher caregiver burden. These findings demonstrate the negative impact of FTLD on individuals and caregivers.
Effect of Patient Characteristics on Reported Outcomes Over 12 Months Following Lumbar Radiofrequency Ablation: A Retrospective Review of 500 Patients
Yadav, Abhishek , Hagedorn, Jonathan M. , D’Souza, Ryan S. , Engle, Alyson M. , Hagedorn, Jonathan M , D'Souza, Ryan S , Deer, Timothy R.

Mayo Clinic

Pain Practice | July 12, 2020 | Volume: 21 | Issue: 2 | Pages: 152-159

10.1111/papr.12938 | PMID 32654319 Get It

AbstractBackgroundLow back pain is the leading cause of years lost to disability worldwide. Approximately 15% to 45% of chronic low back pain is due to facet joint arthropathy. Currently, no large‐scale retrospective studies have investigated long‐term clinical predictors of success in individuals receiving radiofrequency ablation (RFA) of the medial branches for facet joint arthropathy.ObjectiveTo determine the clinical factors associated with success and failure of RFA of lumbar facet joints at 1‐year follow‐up.MethodsClinical data were gathered from 500 consecutive patients with an International Classification of Diseases (ICD)‐10 diagnosis of lumbar spondylosis. VAS pain scores for patients undergoing lumbar medial branch RFA procedures were recorded at multiple time points, up to the 1‐year follow‐up visit. A responder was defined as having ≥30% improvement in VAS score from the pre‐procedural VAS score. For our primary analysis, regression analysis was conducted to identify associations between responder status and patient characteristics, including age, gender, body mass index (BMI), hormone use, opiate dose, and smoking history at multiple time points, up to the 1‐year follow‐up visit.ResultsA total of 500 patients were included in the study. At the 1‐year post‐RFA follow‐up visit, responder status was associated with a lower rate of prior opioid use (43.22% vs. 55.76%, odds ratio 0.60 [95% confidence interval (CI) 0.40 to 0.92], P = 0.018), lower pre‐procedural opioid consumption in oral morphine equivalents (10.16 ± 16.02 vs. 14.67 ± 20.65, β −4.50 [95% CI −8.57 to −0.44], P = 0.030), and a higher pre‐VAS pain score (6.36 ± 2.17 vs. 5.85 ± 2.17, β 0.50 [95% CI 0.06 to 0.95], P = 0.028). There were no significant associations between responder status and age, gender, BMI, hormone use, and smoking history at the 1‐year follow‐up visit.ConclusionsOur results suggest that patients prescribed opioids, particularly at higher dosages, may find less pain relief 1 year following RFA for facetogenic pain. Additionally, patients with higher pre‐procedural VAS pain scores may be more likely to have a positive response at 1 year.
The Difference in Medial Meniscal Extrusion between Non‐Weight‐Bearing and Weight‐Bearing Positions in People with and without Medial Compartment Knee Osteoarthritis
Reisner, Jacob H. , Franco, John , Johnson, Adam C. , Sellon, Jacob L. , Finnoff, Jonathan T. , Finnoff, Jonathan T , Hollman, John H.

Mayo Clinic

PM&R | July 11, 2020 | Volume: 13 | Issue: 5 | Pages: 470-478

10.1002/pmrj.12450 | PMID 32652849 Get It

BackgroundMedial meniscal extrusion (MME) has been correlated with medial meniscal injury and progression of medial knee osteoarthritis (OA).ObjectiveTo examine the difference in MME between non‐weight‐bearing (supine) and weight‐bearing (standing) positions in patients with and without medial knee OA. Determine the correlation between body mass index (BMI), Kellgren‐Lawrence (KL) grade, Knee Osteoarthritis Outcome Score (KOOS), and MME.DesignProspective.SettingTertiary institution PM&R Department.ParticipantsForty five participants (29 female, 16 male), 24 with healthy knees and 21 with OA.Methods or InterventionsA single physician sonographer measured supine and standing MME with ultrasound (US) on each participant. The physician was blinded to all measurements. BMI was recorded on all participants. KL grades and KOOS questionnaires were obtained for the OA group.Main Outcome MeasuresMME in supine and standing positions, change in MME from supine to standing, BMI, KL grade, and KOOS subscale scores.ResultsMME increased .52 mm from supine to standing (P < .001). MME was greater in the OA group in both the supine (P = .002) and standing (P < .001) positions. Increasing BMI was moderately correlated with increasing MME (supine P = .001, standing <.001). Increasing age was correlated with increasing MME (supine P = .012, standing P = .002). Increasing KL grade (from 1 to 4) was correlated with increasing MME (supine P = .015, standing = .006). There was a small‐to‐moderate correlation between KOOS activities of daily living (ADL) subscale score and change in MME from supine to standing (P = .035). The change in MME from supine to standing positions had a small‐to‐moderate correlation (P = .035) with KOOS ADL subscale score alone but did not correlate with any of the other KOOS subscale scores or KOOS total scores. Receiver operating characteristic curve analysis suggested a standing MME value of 4.2 mm provides a positive likelihood ratio of 6.02 for knee OA.ConclusionsMME is greater in those with OA and with weight‐bearing. MME correlates with BMI, age, KL grade, and the KOOS ADL subscale score. Finally, standing MME of 4.2 mm yielded a higher positive likelihood ratio to differentiate between healthy knees and those with medial compartment OA than the previously reported value of 3.0 mm.
Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges
Long, Thomas A., Bashleben, Christine , Fink, Susan L. , Rudolf, Joseph W. , Peterson, Daniel J. , Wener, Mark H. , Baltaro, Richard J., Genzen, Jonathan R. , Ansari, M. Qasim , Rhoads, Daniel D. , Rhoads, Daniel D , Willrich, Maria Alice V. , Linden, Michael A.

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | July 10, 2020 | Volume: 59 | Issue: 1 | Pages: e19-e22

10.1515/cclm-2020-0697 | PMID 32628626 Get It